Ok, again, not being debbie downer here, but QB STATUS IS NOT A LAUNCHPAD CATALYST for an OTC stock!!! It's just not. Many QB OTC's go down and are manipulated just as easily as non-qb.
Usually, imo, it seems as if OTC's have so many shares outstanding that IF they are actually legit, a RS is needed to even consider uplisting to a big exchange.
Biopharma's are a little different monster as they can easily be bought out with ONE huge discovery and/or may get to a price level on speculation where no RS is needed. The OS on this one doesn't seem too bad, but a $4 price still very far away.
It also seems as this was the big news everyone was waiting for and price was up nicely and not complaining about a 30%+ gain, but I don't think I'm alone thinking it would have triggered much higher volume and near 100% gain. We'll see how many flippers there are the day after to see how this holds, but IF they announce positive results on the next lag, then I think things may go to a whole new level and we'll surpass the .25 mark with ease.
If waiting to release other PR's after QB, IMO, if price shoots up big it will be because of the PR's and not the QB.
Good luck
-OUT-
News 
Market Data 
Discover 
AI
